TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOM… (NCT07509905) | Clinical Trial Compass
CompletedNot Applicable
TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
Egypt34 participantsStarted 2025-10-15
Plain-language summary
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous electrical acupoint stimulation for cisplatin- chemotherapy induced nausea and vomiting.
Who can participate
Age range40 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male and female patients who their ages between 40 and 60.
* All patients diagnosed with cancer and planned to receive TACE treatment with cisplatin (60 mg) as the main drug. The chemotherapy regimen will not include steroids.
* Karnofsky's score ≥60.
* All patients will receive the same antiemetic drug.
* None of them receiving other physical therapy modalities to treat nausea and vomiting.
* The skin of acupoint site receiving electrical acupoint stimulation must be intact and without visible evidence of injury
* All patient can tolerate mild discomfort following electrical stimulation.
* All patients enrolled in the study will have their informed consent.
Exclusion Criteria:
* Combined use of other venous chemotherapy within 5 days after Transarterial Chemoembolization
* Other confounding factors that may cause nausea and vomiting (such as intestinal obstruction, anorexia, and so on)
* Having vomited or used 5 HT3 receptor antagonists or other antiemetics within 24 hours before Transarterial Chemoembolization .
* Receiving concurrent radiotherapy
* Severe uncontrolled complications and unstable metastases
* Installing pacemaker, Pregnancy.
* History of convulsions or seizure disorder.
* Cognitive dysfunction, unable to finish Scale
* Transcutaneous electrical acupoint stimulation treatment within the past year regardless of indication.
What they're measuring
1
Assessment of nausea
Timeframe: At the day of chemotherapy administration and the following 5 days